Novel agents should be considered as complementary to high dose therapy for treating multiple myeloma rather than alternatives to it, delegates heard at the EHA congress. This was from Jesus San-Miguel from the University of Salamanca in Spain who presented latest data on the effectiveness of autologous transplantations and the use of first, second and third generation novel agents. He gave ecancer tv his assessment of the role of the newest novel agents and about the anti-myeloma effect of using drugs to combat bone disease.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).